Syringe labelling
We comply with the ISO 26825 standard and the DIVI and DGAI recommendations for the manufacture of our syringe labels. This allows us to contribute to a reduction in substance mix-ups and increase patient safety.
-
ISO labels 79.8300.557
Adhesive labels acc. to ISO 26825, helps avoiding false medication by color-coding of drug classes, labels antagonists in distinctive diagonal stripe design, size 35 mm x 13 mm, reel with 1000 pcs.
-
DIVI labels 79.8300.558
Adhesive labels acc. to DIVI, helps avoiding false medication by color-coding of drug classes, labels antagonists in distinctive diagonal stripe design, size 80 mm x 40 mm, reel with 500 pcs.
-
DIVI background label R 79.8360.004
DIVI background label R, Label documenting signature, time and date, substance quantity and total quantity (German), Font color: black, Background: white, Style: unicolor, Size: 80x40mm, reel with 500 pcs.
-
DIVI background label 79.8360.003
DIVI background label B, Label documenting signature, time and date, substance quantity and total quantity (German), Font color: black, Background: white, Style: unicolor, Size: 80x40mm, 100 sheets with 12 pcs. ea
-
Customized label 79.8300.560
Self-adhesive labels, special design, 13 x 35 mm, minimum order 6 rolls
General
-
+
Why have some letters recently been capitalised in the middle of the word for certain compounds?
This is the 'tall man lettering' principle. The optical distinguishability is increased by putting certain letters in capitals, for example NIFEdipine and niCARdipine.
-
+
What does the abbreviation DIVI stand for?
The DIVI (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin [German Interdisciplinary Society for Intensive and Emergency Medicine]) is a group comprising personal members, scientific societies and professional associations, with the aim of promoting intensive medicine.
-
+
Do the ISO 26825 and DIVI recommendations differ from one another?
Until 2012, the 'recommendations on the labelling of tips in intensive and emergency medicine' were merely a supplement to ISO 26825. As a result of the revision in 2012, the updated recommendations from the DIVI do now deviate from the guidelines set out in ISO 26825 in some cases. Among other things, this relates to the changing of the colour code for muscle relaxants, the use of white text for certain compounds, the use of the tall man lettering principle and the new groups 'cholinergics' and 'coagulants'.
-
+
Why are some letters capitalised in the middle of the word for certain compounds?
This is the 'tall man lettering' principle. The optical distinguishability is increased by putting certain letters in capitals, for example NIFEdipine and niCARdipine.